{"id":"proxibarbal","rwe":[{"pmid":"7901885","year":"1993","title":"[Thrombopenic purpura caused by proxibarbal].","finding":"","journal":"La Revue de medecine interne","studyType":"Clinical Study"},{"pmid":"1355933","year":"1992","title":"[Peripheral thrombopenia secondary to proxibarbal therapy].","finding":"","journal":"Therapie","studyType":"Clinical Study"},{"pmid":"1969721","year":"1990","title":"[Immuno-allergic thrombopenia caused by proxibarbal].","finding":"","journal":"Annales de medecine interne","studyType":"Clinical Study"},{"pmid":"2696937","year":"1989","title":"[A controlled trial of prevention of recurrence of gastroduodenal ulcers with proxybarbital].","finding":"","journal":"Polski tygodnik lekarski (Warsaw, Poland : 1960)","studyType":"Clinical Study"},{"pmid":"2890197","year":"1987","title":"[Treatment of psycho-neuro-autonomic disorders of menopause: contribution of veralipride compared with a barbiturate sedative (proxibarbal)].","finding":"","journal":"Revue francaise de gynecologie et d'obstetrique","studyType":"Clinical Study"}],"tags":[{"label":"proxibarbal","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N05CA22","category":"atc"},{"label":"Active","category":"status"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Hypnotics and Sedatives","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PROXIBARBAL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:06:54.167421+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:06:59.605196+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROXIBARBAL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:06:59.904411+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Monoamine oxidase A activator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:00.970986+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2105233/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:07:00.621609+00:00"}},"allNames":"ipronal","offLabel":[],"synonyms":["proxibarbal","centralgol","hydroxydial","ipronal","proxibarbital"],"timeline":[],"approvals":[],"brandName":"Ipronal","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"proxibarbal","explanation":"","oneSentence":"","technicalDetail":"Ipronal is a proxibarbal, a class of compounds that have been shown to have anxiolytic and sedative effects in animal studies. Its exact mechanism of action is thought to involve the modulation of GABA receptors, which can lead to changes in neuronal activity and neurotransmitter release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2322","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROXIBARBAL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:31:06.114181","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:02.287292+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"pentobarbital","drugSlug":"pentobarbital","fdaApproval":"1973-09-19","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"amobarbital","drugSlug":"amobarbital","fdaApproval":"","relationship":"same-class"},{"drugName":"secobarbital","drugSlug":"secobarbital","fdaApproval":"1950-07-19","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"talbutal","drugSlug":"talbutal","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methohexital","drugSlug":"methohexital","fdaApproval":"1960-06-27","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"thiopental","drugSlug":"thiopental","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"proxibarbal","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"pentobarbital","brandName":"pentobarbital","genericName":"pentobarbital","approvalYear":"1973","relationship":"same-class"},{"drugId":"amobarbital","brandName":"amobarbital","genericName":"amobarbital","approvalYear":"","relationship":"same-class"},{"drugId":"secobarbital","brandName":"secobarbital","genericName":"secobarbital","approvalYear":"1950","relationship":"same-class"},{"drugId":"talbutal","brandName":"talbutal","genericName":"talbutal","approvalYear":"","relationship":"same-class"},{"drugId":"methohexital","brandName":"methohexital","genericName":"methohexital","approvalYear":"1960","relationship":"same-class"},{"drugId":"thiopental","brandName":"thiopental","genericName":"thiopental","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005338","UNII":"F97OMS297F","CHEBI":"CHEBI:134928","INN_ID":"3734","RXNORM":"83885","UMLSCUI":"C0288495","chemblId":"CHEMBL2105233","ChEMBL_ID":"CHEMBL2105233","KEGG_DRUG":"D07324","DRUGBANK_ID":"DB13253","PUBCHEM_CID":"17336","MESH_SUPPLEMENTAL_RECORD_UI":"C084552"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":10,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05CA22","allCodes":["N05CA22"]},"biosimilarFilings":[],"recentPublications":[{"date":"1993 May","pmid":"7901885","title":"[Thrombopenic purpura caused by proxibarbal].","journal":"La Revue de medecine interne"},{"date":"1992 Jan-Feb","pmid":"1355933","title":"[Peripheral thrombopenia secondary to proxibarbal therapy].","journal":"Therapie"},{"date":"1990","pmid":"1969721","title":"[Immuno-allergic thrombopenia caused by proxibarbal].","journal":"Annales de medecine interne"},{"date":"1989 Apr 10-17","pmid":"2696937","title":"[A controlled trial of prevention of recurrence of gastroduodenal ulcers with proxybarbital].","journal":"Polski tygodnik lekarski (Warsaw, Poland : 1960)"},{"date":"1987 Jul-Sep","pmid":"2890197","title":"[Treatment of psycho-neuro-autonomic disorders of menopause: contribution of veralipride compared with a barbiturate sedative (proxibarbal)].","journal":"Revue francaise de gynecologie et d'obstetrique"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:07:02.287292+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":false,"score":0}}